Data from the TCGA revealed that CYP1A2 expression is significantly elevated in tumor tissues compared to normal tissues, highlighting its potential role in bladder cancer development and its promise as a therapeutic target (Figures S1 and S2). This evidence concerns the gene CYP1A2 and urinary bladder cancer.